Summit Therapeutics Share Discussion Threads

[freedosh] 26/10/2016 15:22

High volume in US.

[someuwin] 26/10/2016 15:04

Summit Therapeutics ‏@Summitplc · 8m8 minutes ago

We're at @Child_Neurology Society in Vancouver this week w/@JettFoundation. Come see us at the #Duchenne clinical trials symposium Friday!

[sorrento06] 26/10/2016 12:12

Big buy at 10, about £47k

[hugus maximus] 26/10/2016 09:27

tightfist .. absolutely! GLA HM

[tightfist] 26/10/2016 09:17

Hugus,Agreed. The experts are openly expressing dissatisfaction that the approval of Etil. is flawed and that the efficacy bar has been set low. Our better-designed EZD trials, hopefully with sound results should be well received - especially when they also address the other 87% of the DMD community which Etil. cannot treat in the meantime.It's an interesting twist that the approval of a "competitor" has rapidly moved Summit forward, together with the potential availability of EZD for all the suffering families.Cheers, tightfist

[waterloo01] 25/10/2016 16:12

No kidding!

[chrisatrdg] 24/10/2016 17:29

Is Momentum Mounting for Summit Therapeutics Plc (SMMT)



Edit: I hope so !!

What Next For Summit Therapeutics PLC Stock After Today’s Huge Increase?



Edit: The increase finished not so high but good to see further cover.

[football] 24/10/2016 15:02

Yep freedosh your right and i also like this in the header now


Oct 2016 - JMP Securities SMMT target $42. (SUMM equivalent £6.80)

[freedosh] 24/10/2016 14:25

Would be much higher if Zacks outdated report ignored
They should have used median rather than mean

[football] 24/10/2016 14:14

Summit Therapeutics PLC (SMMT) Receives $23.80 Average PT from Brokerages
Posted by Dave Schultz on Oct 24th

[freedosh] 24/10/2016 12:01

O/T
Suggest folks just open a US E*Trade account. Easy peasy

[hugus maximus] 24/10/2016 11:55

Thanks Waterloo ... so not the easiest of scenarios for UK investors. For that reason alone, I agree that Summit won't be considering this.

[waterloo01] 24/10/2016 10:45

This is a non issue, however you can trade US equities with most brokers, however you usually have to jump through some hoops to show you are a 'sophisticated' investor.

Situation here - at present - is very different as we are trading actively on AIM.

[hugus maximus] 24/10/2016 10:39

Thanks Solomon .. so if using an online stockbroker account to buy and sell the AIM share, can you continue to trade on the NASDAQ with UK access to buying and selling online? And indeed ... throwing a curve ball here ... is this a relationship that might continue in its current form if trade agreements change with the EU?

BTW - IMHO Summit will continue trading on AIM anyway.

[solomon] 24/10/2016 09:45

When Verizon de-listed on the London exchange, my LSE shares were simply converted into NYSE shares. VZC became VZ. I'm not sure I did that well but it went smoothly.

[hugus maximus] 24/10/2016 09:29

Someuwin - under the circumstances you suggest, what is the process for shareholders with AIM shares to carry on investing?

[someuwin] 23/10/2016 22:17

I notice that GW Pharmaceuticals (LSE:GWP) has last week announced that it will be cancelling its AIM listing to remain a pure NASDAQ stock.

Considering that there is considerably more volume traded on NASDAQ:SMMT than LSE:SUMM and that there is more appetite for Phara stocks over there than here, I reckon it might be a good move for Summit to cancel its AIM listing too.

Not only would it save money on duplicate listing fees but it would also prevent sluggish AIM performance fron holding back the US listing.

GWP Listed on AIM in 2001.
Dual listed on NASDAQ 2013.
Cancels AIM listing 2016.

[hugus maximus] 23/10/2016 10:39

Agreed luminoso ... I have an additional worry about Sarapeta:

There's surely a possibility that the point where EZD is seen to be transforming Summit's fortunes exponentially, coincides with the FDA coming back to bite Sarepta in the bum if Eteplirsen is shown in a year or so, to do nothing to significantly help DMD sufferers?(for its $300,000 price tag per patient.)

Surely there will be ongoing data gathering from the Etepliresen roll out that will have to categorically prove it works to the FDA ... perhaps there's still a question mark there?

IMHO, we do not want to be strapped for ever to Sarapeta.

[solomon] 22/10/2016 22:20

I think you can be assured your contentment is showing through reasonably well luminoso.

[luminoso] 22/10/2016 19:48

Far be it from me to diss Sarepta after they rescued our share price from the ignominy of a potentially jaw droppingly dilutive placing, BUT I hope that the nasdaq punters can now see that a drug that has the potential to successfully treat 100% of DMD sufferers is worth more than a drug that probably won't do a lot of good for 13% of them. A RDZ deal would kill off the speculation that SRPT might buy us any time soon.
Quite frankly, they won't be able to afford us after that, although they might be able to shell out for a little percentage of US rights one day. If our drugs fulfil their promise, we will make SRPT look like small beer. Not sure if my contentment to be a Summit share holder is showing through enough in this post ?

[hugus maximus] 22/10/2016 09:56

freemoney - I also saw the Sarepta / Summit independent share price move as good news. Although Sarepta's financial injection in return for some EZD territory rights involvement with Summit has been transformational, I should not wish our paths to be interdependent forever more.

There does seem to have been correlation in the movement of SRPT and SUMM share price since the deal and I wonder if positive analysts report updates for SMMT this week (e.g. Credit Suisse & N+1 Singer) are responsible for Summit's independently moving up on Friday?

Hopefully the NASDAQ sees Summit as an independent entity and not simply "a company that Sarepeta should have bought but may well still decide to do if EZD goes well".

[freemoney1] 22/10/2016 01:14

Satepta down and we're up. Shows Summit individual strength and awareness of potential. Hopefully correction will continue next week. GLA

[waterloo01] 21/10/2016 18:48

This is looking a little better, but still a long way from the recent high. US traders will decide on where it settles, short term at least, until we get details on what the next steps are for RDZ. Hopefully we will have a partner to do the heavy lifting and with a significant % retained. If it mirrors the SRPT deal I'd be happy with that.

[someuwin] 21/10/2016 18:09

Summit Therapeutics Retweeted
MuscularDystrophyUK ‏@MDUK_News 3 hours ago

Missed last week's Q&A with Prof Dame Davies & @Summitplc? Read the full transcript here #Duchenne #utrophin